Novo Nordisk A/S$44.73GILD · NASDAQ-GS
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $29.44B | $28.75B | $27.12B | $27.28B | $27.30B | $24.69B | $22.45B | $22.13B |
| Cost of Revenue | $6.23B | $6.25B | $6.50B | $5.66B | $6.60B | $4.57B | $4.67B | $4.85B |
| Research & Development | — | — | — | — | — | — | $9.11B | $5.02B |
| Selling, General & Administrative | $5.77B | $6.09B | $6.09B | $5.67B | $5.25B | $5.15B | $4.38B | $4.06B |
| Operating Expenses | $19.42B | $27.09B | $19.51B | $19.95B | $17.39B | $20.62B | $18.16B | $13.93B |
| Operating Income | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B | $4.07B | $4.29B | $8.20B |
| Interest Expense | — | — | $944.00M | $935.00M | $1.00B | $984.00M | $995.00M | $1.08B |
| Other Income / (Expense) | $798.00M | $6.00M | $198.00M | -$581.00M | -$639.00M | -$1.42B | $1.87B | $676.00M |
| Income Before Taxes | $9.80B | $690.00M | $6.86B | $5.81B | $8.28B | $1.67B | $5.16B | $7.80B |
| Provision for Income Taxes | $1.29B | $211.00M | $1.25B | $1.25B | $2.08B | $1.58B | -$204.00M | $2.34B |
| Net Income | $8.51B | $480.00M | $5.67B | $4.59B | $6.22B | $123.00M | $5.39B | $5.46B |
| Basic EPS | $6.84 | $0.38 | $4.54 | $3.66 | $4.96 | $0.10 | $4.24 | $4.20 |
| Diluted EPS | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 | $0.10 | $4.22 | $4.17 |
| Basic Shares Outstanding | 1.24B | 1.25B | 1.25B | 1.25B | 1.26B | 1.26B | 1.27B | 1.30B |
| Diluted Shares Outstanding | 1.25B | 1.25B | 1.26B | 1.26B | 1.26B | 1.26B | 1.28B | 1.31B |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | -$0.78 | -$1.05 | -$0.65 | 9 | ↑4 ↓1 |
| Dec 2027 | $9.73 | $9.10 | $11.20 | 11 | ↑3 ↓2 |
| Dec 2028 | $9.87 | $9.11 | $10.43 | 4 | ↑1 ↓0 |
| Dec 2029 | $9.62 | $9.62 | $9.62 | 1 | ↑0 ↓0 |
